ClinicalTrials.gg
CompletedNCT05815901EPICUpdated May 4, 2026

A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients

A Phase 3 interventional study of Epaminurad 6 mg and Epaminurad 9 mg in Gout, sponsored by JW Pharmaceutical. Completed at 1 site in South Korea. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by JW Pharmaceutical · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
612
Allocation
Randomized
Ages
19 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing febuxostat in Gout — 1 open to participants now, 1 under way, none of them phase 3. Febuxostat · Gout.

Enrollment
6th of 29
612 · median 109
Started
2023
with 1 other
Phase 3
10 of 29
none open now
Registered
28th of 29
by date
Lead sponsor
1 of 29
JW Pharmaceutical

Among the 29 studies testing febuxostat in Gout, this one is the 6th largest by enrollment, is one of 2 that started in 2023, is one of 10 in phase 3, and was the 28th registered.

Gout

347 studies on the registry are indexed under Gout; 49 are open to participants now.

Browse Gout studies →

Open to participants now

1 of the 29 studies testing febuxostat in Gout is open now. Recruiting first, the newest first:

About febuxostat

Febuxostat: first FDA approval 2009 (ULORIC), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 30 Gout studies recruiting now, 14 (47%) set no upper age limit and 10 (33%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 19 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing febuxostat in Gout, or all of them as a file.
02

Study summary

A phase 3 clinical trial to compare and evaluate efficacy and safety of epaminurad with febuxostat in gout patients.

03

Conditions studied

  • Gout

Browse trials for

04

Who can participate

Ages eligible
19 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • for screening

    1. ≥19 to ≤75 years of age at the time of written
    2. Diagnosed record with gout, or ACR/EULAR 2015 score ≥8
    3. Able and willing to actively participate in TLC programme
    4. Signed ICF for voluntary study participation
  • for randomization

    1. sUA level ≥7.0 mg/dL
    2. ACR/EULAR 2015 score ≥8

Exclusion criteria

Exclusion Criteria:

  1. Medical history

    Malignant tumor, Urolithiasis within 5 years, disease, Lesch-Nyhan syndrome, Hereditary problems, Ischemic heart disease, Prior or planned organ transplant recipient.

  2. Concurrent disease or laboratory test abnormality

    Uncontrolled diabetes mellitus, Uncontrolled hypertension, Uncontrolled dyslipidemia, or ALT ≥2×, total ≥1.5×ULN, \<30 mL/min/1.73m\^2, Uncontrolled thyroid dysfunction, , or positive, Drug and alcohol abuse, ≥40 kg/m\^2

  3. History of gout flare between 2 weeks before written and immediately before randomization
  4. Any cardiovascular abnormalities that might affect the study
  5. Prior or planned treatment with xanthine oxidase inhibitors, uricosuric agents, or uricolytic agents
  6. Prior or planned treatment with drugs acting on human uric acid transporter 1 or diuretics
  7. Prior or planned treatment with intravenous and oral high dose systemic , mercaptopurine, azathioprine, or theophylline
  8. Hypersensitivity to the IP (epaminurad or febuxostat)
  9. Pregnant or lactating woman.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
612 participants (actual)

Study arms

  • Experimental
    Epaminurad 6 mg

    \[Main study period\] Epaminurad 6 mg and three matched placebos for 20 weeks. \[Extension study period\] Epaminurad 6 mg or 9 mg (open label) for 28 weeks.

    Drug: Epaminurad 6 mg · Drug: Epaminurad 9 mg placebo · Drug: Febuxostat 40 mg placebo · Drug: Febuxostat 80 mg placebo

  • Experimental
    Epaminurad 9 mg

    \[Main study period\] Epaminurad 9 mg and three matched placebos for 20 weeks. \[Extension study period\] Epaminurad 6 mg or 9 mg (open label) for 28 weeks.

    Drug: Epaminurad 9 mg · Drug: Epaminurad 6 mg placebo · Drug: Febuxostat 40 mg placebo · Drug: Febuxostat 80 mg placebo

  • Active comparator
    Febuxostat 40 mg

    \[Main study period\] Febuxostat 40 mg and three matched placebos for 20 weeks. \[Extension study period\] Epaminurad 6 mg or 9 mg (open label) for 28 weeks.

    Drug: Febuxostat 40 mg · Drug: Epaminurad 6 mg placebo · Drug: Epaminurad 9 mg placebo · Drug: Febuxostat 80 mg placebo

  • Active comparator
    Febuxostat 80 mg

    \[Main study period\] Febuxostat 80 mg and three matched placebos for 20 weeks. \[Extension study period\] Epaminurad 6 mg or 9 mg (open label) for 28 weeks.

    Drug: Febuxostat 80 mg · Drug: Epaminurad 6 mg placebo · Drug: Epaminurad 9 mg placebo · Drug: Febuxostat 40 mg placebo

Interventions

  • Epaminurad 6 mg tablet

  • Epaminurad 9 mg tablet

  • Febuxostat 40 mg tablet

  • Febuxostat 80 mg tablet

  • DrugEpaminurad 6 mg placebo

    Placebo tablet

  • DrugEpaminurad 9 mg placebo

    Placebo tablet

  • DrugFebuxostat 40 mg placebo

    Placebo tablet

  • DrugFebuxostat 80 mg placebo

    Placebo tablet

06

What researchers measure

Primary outcomes

  1. Proportion of subjects with sUA (serum uric acid) <6 mg/dL at the last 3 time points during the main study period

    Time frame: Week 24

Secondary outcomes

  1. Proportion of subjects with sUA <6 mg/dL post-dose at each visit

    Time frame: up to Week 24

  2. Proportion of subjects with sUA <5 mg/dL at the last 3 time points

    Time frame: Week 16, 20, 24

  3. Proportion of subjects with sUA <5 mg/dL post-dose at each visit

    Time frame: up to Week 24

  4. Change from baseline in sUA (mg/dL) at each visit

    Time frame: up to Week 24

  5. Percent change from baseline in sUA at each visit

    Time frame: up to Week 24

  6. Incidence of gout flare post-dose up to Week 24

    Time frame: up to Week 24

  7. Proportion of subjects who had rescue therapy for gout flare post-dose up to Week 24

    Time frame: up to Week 24

  8. Adverse events

    Safety endpoint

    Time frame: up to Week 52

  9. Number of subjects with clinical significant results of Laboratory tests

    Safety endpoint

    Time frame: up to Week 52

  10. Number of subjects with clinical significant results of Vital signs

    Safety endpoint

    Time frame: up to Week 52

  11. Number of subjects with clinical significant results of Electrocardiogram

    Safety endpoint

    Time frame: up to Week 52

07

Study locations

1 site
  • Inha University Hospital
    Incheon, South Korea
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Mar 2024, 12 months.

Of 21 phase 3 interventional studies under Gout, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 25. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2023
First posted
Apr 18, 2023
StartActual
Mar 21, 2023
Primary completionActual
Mar 26, 2024
CompletionActual
Apr 23, 2026
Last update
May 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05815901
Lead sponsor
JW Pharmaceutical
Responsible party
Sponsor
First posted
Apr 18, 2023
Start date
Mar 21, 2023
Primary completion
Mar 26, 2024
Completion
Apr 23, 2026
Last update
May 4, 2026

Study contacts

Won Park, MD
study chair · Inha University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Epaminurad · Febuxostat

Start the discussion